BMO Capital analyst Evan Seigerman lowered the firm’s price target on Biogen (BIIB) to $139 from $156 and keeps a Market Perform rating on the shares after its Q4 results and FY25 guide. The stock’s tough story is “only getting tougher” as revenue erosion continues with unclear path to near-term sustained growth, the analyst tells investors in a research note. The all-important 2025 guide reflects accelerated erosion of the MS business, giving the firm less confidence that newer launches can make up the lost ground, while Skyclarys sales have grown only 2% since Q2 of 2024, BMO added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen price target lowered to $225 from $231 at RBC Capital
- Biogen price target lowered to $135 from $166 at Wedbush
- Biogen price target lowered to $200 from $275 at TD Cowen
- Biogen price target lowered to $157 from $192 at Morgan Stanley
- Biogen (BIIB) Q4 Results Make Analysts Feel Poorly About its Prospects
Questions or Comments about the article? Write to editor@tipranks.com